Leading Japanese CRO Attains Highest Accreditation in Medidata Solutions' ASPire to Win Program



Medidata Solutions announced that CMIC, one of the largest contract research organizations in Japan, has attained Rave Accredited Plus, the most advanced level in Medidata’s ASPire to Win® program for CROs and other service providers. With this accreditation, CMIC can now offer a comprehensive suite of services to implement and support Medidata Rave®, a leading platform for electronic clinical data capture, management and reporting, for a growing customer base in Japan, as well as across Asia.
Since starting its CRO business in 1992, CMIC has grown to become one of the largest CROs in Japan, with several locations throughout Asia and South America. CMIC offers services in several key areas of the clinical trial process, including monitoring and managing data, coordinating clinical research, consulting on pharmaceutical affairs and conducting pre-clinical work. With a vision of driving the development of evidence-based medicine, CMIC has long supported the use of cutting-edge technologies like Medidata Rave in the fast-growing Asian clinical trials market.
Medidata’s ASPire to Win program selects, trains and accredits clinical service providers to deliver Medidata Rave clinical trial technology along with their own project and data management expertise. The program offers CROs and service providers the choice of four enablement levels – Rave Aware, Rave Ready, Rave Accredited and Rave Accredited Plus. CMIC last year attained the Rave Accredited level, which allowed the company to build and configure its customers’ Rave studies, and provide a portfolio of other Rave-related services. As a Rave Accredited Plus member, CMIC now will be able to provide the full suite of Rave-related services, including end-user training, study build, reporting, outputs, integrations and migrations.
“The demand for Medidata Rave in Japan is strong, and as we extend our reach throughout Asia, we expect to see more opportunities to implement Rave and also to integrate Rave with a variety of clinical development technologies,” said Makoto Sato, Corporate Officer, CMIC.

 Medidata first announced ASPire to Win in April 2005 as a partner program designed to enable select CROs and other service providers to offer Medidata Rave implementation services. Since then, ASPire to Win has grown to include more than 20 partners, ranging from smaller clinical consultancies to large, global CROs. For more information about the ASPire to Win program, click the link.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.